INIFY Prostate

by ContextVision  · Based in Sweden → — AI-based decision support for accurate prostate cancer diagnosis.
Oncology Pathology Urology

Overview

It is primarily intended for pathologists and uropathologists in care settings that utilize digital pathology workflows for prostate cancer diagnostics.

  • What it does:INIFY Prostate identifies and outlines suspicious cancer areas in digitized prostate needle biopsy slides stained with H&E. The initial version focuses on identifying cancerous tissues, with future iterations planned to suggest Gleason classifications.
  • How it fits a clinical workflow:The tool integrates into a digital pathology workflow, aiming to streamline the diagnostic process. It can help prioritize pathologists’ worklists by automatically separating slides containing cancer from those that do not, potentially presenting cases with more significant cancer first. This can contribute to more efficient analysis and reporting.
  • Notable capabilities:INIFY Prostate utilizes a patented annotation method called MasterAnnotation in its algorithm training, which contributes to its pixel-level focus in outlining suspicious areas. Clinical evaluations have indicated high sensitivity and specificity in identifying cancer, even in small foci. The tool is designed to work consistently across images from different pathology labs and scanners. Inify Laboratories emphasizes a specialized workflow dedicated to prostate biopsies, aiming for consistent quality and easily interpretable visual reports for urologists.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-based decision support
  • Accurate outlining of suspicious prostate cancer areas
  • Pixel-level focus through MasterAnnotationu2122
  • High sensitivity (100% for small cancer foci, 99.3-99.8% for larger areas)
  • High specificity (96-98%)
  • Works equally well across different pathology labs and scanners
  • Supports pathologists in daily clinical work
  • Improves diagnostic confidence
  • Worst-case-first reviewing process for workflow management
  • Potential for Gleason grading suggestions (future version)

Use Cases

  • Identifying and outlining suspicious prostate cancer areas in digitized prostate biopsy slides
  • Supporting pathologists in their daily clinical work to increase diagnostic accuracy
  • Improving concordance between pathologists
  • Prioritizing patient cases with higher levels of cancer for diagnosis
  • Reducing inter- and intra-variability in prostate cancer diagnosis
  • Automating image analysis for efficiency and precision

What Physicians Need to Know

Evidence Base (literature scope)
INIFY Prostate is an AI-based, CE-marked decision support tool that identifies and outlines suspicious cancer areas in digitized prostate needle biopsy slides. [2, 4, 5] It utilizes a patented annotation method called MasterAnnotationu2122 for training its algorithms. [1, 3, 9] The tool is supported by peer-reviewed papers, including an evaluation of its diagnostic accuracy independent of preanalytical factors. [4, 7]
Clinical Validation Studies
Clinical evaluations have shown INIFY Prostate to accurately outline suspicious prostate cancer. [1] A US clinical evaluation, presented at the Pathology Visions Congress in 2021, involved two independent pathologists reviewing predictions on prostate biopsy slides from 30 patients across two medical centers and three different scanners. [1] This study demonstrated 100% sensitivity for images with small cancer foci (u22641 mm) and 99.3u201399.8% sensitivity for larger cancer areas, with a high specificity of 96u201398%. [1, 7] The study concluded that INIFY Prostate performs consistently across different pathology labs and scanners. [1, 7] The Pan-European multicenter clinical study 'FirstPath' also evaluated INIFY Prostate's performance in routine clinical practice across four sites, reviewing over 300 biopsy images from 48 patients. [3] This study reported a high sensitivity of 98% and specificity of 96% for correct cancer diagnosis, demonstrating robustness across sites, tissue preparation, scanning, and pathologists. [3] Another clinical evaluation studied the tool's ability to improve accuracy, concordance, and diagnostic confidence among pathologists. [5]
Alert Fatigue Management
INIFY Prostate aims to reduce pathologist workload and anxiety by reliably finding even the smallest cancer foci. [1, 5, 6] It presents cases with the most suspicious areas first, with an automatic calculation of the suspicious cancer area percentage in each slide, which can help streamline the review process. [3, 9]
Differential Diagnosis Support
The tool's primary function is to identify and outline areas suspicious for carcinoma in digitized prostate needle biopsy slides, aiding in prostate cancer detection and segmentation. [4, 5] It also supports Gleason grading. [4, 6, 9]
Clinical Workflow Integration
INIFY Prostate is designed for seamless integration into fully digitalized pathology workflows. [2, 5, 8] It pre-predicts and makes all slides examination-ready when a case is opened, and can present pathologists' worklists in a 'worst-first' order. [3, 9] The system is built to support efficient and standardized processes, aiming to save time for pathologists and ensure objective, consistent, and accurate evaluation of biopsies. [6, 8, 14]
Decision Audit Trail
While not explicitly detailed for INIFY Prostate, the importance of audit trails in electronic medical records for accountability and tracking changes is recognized in the healthcare industry. [23] Inify Laboratories emphasizes smooth, traceable logistics and process management systems that enable traceability in every step, from sample transport to final diagnosis. [11, 14]
Physician Tip

INIFY Prostate is an AI-powered tool designed to enhance the accuracy and efficiency of prostate cancer diagnosis from digitized biopsy slides. Pathologists should leverage its high sensitivity and specificity for identifying suspicious cancer areas, especially small foci, to increase diagnostic confidence and reduce the anxiety associated with missing important findings. The 'worst-first' presentation of cases and slides can help prioritize workload. The tool's robustness across different lab preparations and scanners suggests reliable performance in varied clinical settings. It is important to remember that this tool is a decision support system and the final diagnosis is always performed by a pathologist. [1, 3, 5, 6, 9, 14]

INIFY Prostate is an AI-based, CE-marked decision support tool that seamlessly integrates with hospital LIS systems and is designed for fully digitalized pathology workflows. [2, 8] It processes whole slide images (H&E stained) and is deployed as an external service. [4] The system is scalable for handling large volumes of patient samples and can be replicated in new locations. [14] Inify Laboratories also offers integrated services spanning from early sample handling to final diagnosis, optimizing quality and response times through a fully digital, standardized, and AI-assisted workflow. [14]

Details

Category Clinical Decision Support & Reference, Oncology AI, Pathology AI
Pricing Unknown
DeploymentExternal service
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Unknown
Integrations
EHR Not specified
Specialties Oncology, Pathology, Urology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate INIFY Prostate

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for INIFY Prostate.

View all on YouTube

Frequently Asked Questions

INIFY Prostate is an AI-based, CE-marked decision support tool designed to seamlessly integrate into a fully digitalized pathology workflow. It identifies and outlines suspicious cancer areas in digitized prostate biopsy samples, aiming to support pathologists in their daily clinical work and improve diagnostic confidence.
Clinical evaluations have shown high accuracy for INIFY Prostate. In one study, it achieved 100% sensitivity for small cancer foci (u22641 mm) and 99.3-99.8% sensitivity for larger cancer areas, with a high specificity of 96-98%. The tool has also demonstrated robustness across different labs, tissue preparations, scanners, and pathologists.
While INIFY Prostate has shown strong performance, one study noted a limitation in that both participating laboratories were academic centers, suggesting a need for additional studies to assess performance in community hospitals and reference laboratories. The effectiveness of AI tools can also be influenced by variations in image quality, though INIFY Prostate aims to minimize these through standardized processes.
Alternatives to AI-powered decision support tools like INIFY Prostate include other AI solutions for prostate pathology such as Aira Matrix, ArteraAI, Deep Bio, Ibex Medical Analytics, and Mindpeak. For initial prostate cancer screening and risk assessment, alternatives to biopsy include enzyme tests (like PSA), watchful waiting, MRI scans, digital rectal exams (DRE), transrectal ultrasounds (TRUS), and urine tests (e.g., PCA3, MiPS).
The provided information does not specify the pricing model for INIFY Prostate. However, the company emphasizes that powerful decision support tools like INIFY Prostate have the potential to save valuable time for pathologists and ensure a more objective, consistent, and accurate evaluation of biopsies, which can indirectly impact costs by improving efficiency.

Related Tools

Stanford University
Stanford University
Clinical Decision Support & Reference
Stanford Online's "AI in Healthcare" program provides a comprehensive overview of artificial intelligence's applications and implications within the medical field.
RADIN Health
RADIN Health
Clinical Decision Support & Reference
RADINA is an AI-powered platform by RADIN Health designed to optimize radiology workflows, enhance diagnostic accuracy, and streamline reporting.
Med-PaLM 2
Google
Clinical Decision Support & Reference
Med-PaLM 2 is a large language model from Google, fine-tuned for healthcare to provide high-quality answers to medical questions and support clinical decision-making.
Pacmed Critical Discharge
Pacmed
Clinical Decision Support & Reference
Pacmed Critical Discharge is an AI tool that predicts the probability of death or readmission within seven days of ICU discharge, providing explainable insights for physicians.
AiZtech Labs
AiZtech Labs
Clinical Decision Support & Reference
AiZtech Labs provides enterprise-grade AI solutions for healthcare, focusing on operational efficiency, diagnostic accuracy, and patient care workflows for providers and health systems.
Stethophone Pro
Sparrow Acoustics
Cardiology AI
Stethophone Pro transforms smartphones into advanced cardiac screening tools, enabling clinicians to capture, interpret, and visualize heart sounds for early detection of cardiovascular diseases.

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-08-05 | First Added: 2026-08-05
AI Tool Finder
AI-powered search. Results may not be comprehensive.